Safety profile of ramelteon from the perspective of physicians and pharmacists: a 20-year real-world pharmacovigilance analysis based on the FAERS database
Abstract Background Ramelteon is the first selective melatonin receptor agonist approved by the FDA, demonstrating significant clinical value in improving sleep latency and sleep quality in patients with insomnia. However, its long-term adverse effects have not been fully evaluated. This study analy...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-025-07127-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|